Welcome to our dedicated page for Mirati Therapeut news (Ticker: MRTX), a resource for investors and traders seeking the latest updates and insights on Mirati Therapeut stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mirati Therapeut's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mirati Therapeut's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Mirati Therapeutics (NASDAQ: MRTX) announced promising clinical data for adagrasib, a potent KRASG12C inhibitor, demonstrating efficacy in patients with advanced solid tumors such as pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancer (BTC). The findings, published in the Journal of Clinical Oncology and presented at the ASCO Plenary Series in April 2023, indicate an overall objective response rate (ORR) of 35%, with 33% for PDAC and 42% for BTC. Adagrasib's safety profile aligns with prior studies on NSCLC and CRC. This Phase 2 data from the KRYSTAL-1 study highlights adagrasib’s potential as a monotherapy, especially given its recent inclusion in the NCCN guidelines for CNS cancers, signaling a pathway toward regulatory approval for additional indications.
Mirati Therapeutics (NASDAQ: MRTX) will announce first quarter 2023 financial results on May 9, 2023, at 4:30 p.m. ET. The event will include corporate updates and a review of financial results. Investors can listen to the call via a live webcast on Mirati's website or by dialing specific U.S. and international phone numbers.
Mirati is committed to developing therapies for cancer, focusing on unmet needs in areas like lung cancer. The company is advancing several promising therapeutics, including KRAZATI® (adagrasib), which targets genetic drivers of cancer. However, investors are reminded that forward-looking statements in the release carry risks and uncertainties, including those associated with COVID-19 and drug development processes.